To beat a dead horse here one more time, the top of line results of CX1739 involved 4 variables. A good statistician could have pulled those results out in an afternoon. The parameters that were looked at were obvious ones, and would have been defined ahead of time as a short list of outcome variables to extract. Thus the notion that intensive post-hoc analysis allowed world-class statisticians to extract some counter-intuitive signal seems ridiculous.
There may have been plenty of other analyses that needed to be explored, but these top-of-line results could have been released in September, within a week of the last patient's data being logged. We'd be in a better situation now if they had presented the top-of-line findings promptly, as they were supposed to.
My take on this: they blundered into the wrong indication, completely mishandled communications about why the trial, which was to take 6 months ended up taking 2 years, and then appeared to sit on the trial outcome for 4 months.
Corx management has demonstrated a lack of strategic vision, ethics and competence. Bad luck has little to do with our predicament.
I need to get out of this stupid stock. At this point, I find it impossible to realistically see a path to profitability for this company because the people running it completely lack judgement.
My difficulty is to accept that I have wiped out a substantial part of my savings, and move on. This is emotionally very difficult.
AI
Market Data 
Markets 
